Drug Trial Radar · NCT06989918
MHB018A Treatment in Patients With Active Thyroid Eye Disease
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Jul 22, 2025
Primary completion
Dec 2026
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) LtdIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to investigate the efficacy, safety, and tolerability of MHB018A, a humanized anti-IGF1R antibody, administered q4W for 6 months, in comparison to placebo, in the treatment of participants suffering from active TED.
Conditions
- Thyroid Associated Ophthalmopathies
Interventions
MHB018ADrug
MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
MHB018A placeboDrug
6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proptosis Responder Rate at Week 24Time frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.